June 2024 – Hughes Hubbard & Reed announced today that it advised diversified biopharmaceutical company ANI Pharmaceuticals in its acquisition of global pharmaceutical company Alimera Sciences.

The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024.

“We believe this is a transformational acquisition for ANI, and one that aligns with our strategy to expand our Rare Disease business and deliver on our purpose of ‘Serving Patients, Improving Lives,’” said President and CEO of ANI Nikhil Lalwani.

The acquisition further strengthens ANI’s Rare Disease business as the largest driver of future growth and will create an attractive Rare Disease growth platform, which is expected to account for approximately 45% of pro forma 2024 revenues with robust growth potential. The transaction also expands ANI’s footprint beyond the U.S. with the addition of Alimera’s direct marketing operations located in Germany, the United Kingdom, Portugal and Ireland, as well as its partnerships in Europe, Asia and the Middle East.

Ken Lefkowitz and Scott Naturman led the Hughes Hubbard team with assistance from partners Andy Braiterman, Michael DeBernardis, Philip Giordano, Steve Greene, Patrice Jean, Gary Simon, Shahzeb Lari, Gerold Niggemann, Charles Wachsstock and Javad Husain; counsel Justin Cohen, Erin DeCecchis, Anna Hamati, Kristin Millay, Carol Remy and Sabrina Silverberg; associates Radina Angelova, Justin Campbell, Gabby Gorelik, Tom Koziel and Taylor Skaggs; and paralegal Kathyann Saunders.

The deal was covered by Law.com and The Deal.

About Hughes Hubbard
Hughes Hubbard & Reed LLP is a New York City-based international law firm with a relentless focus on providing quality service to our clients and delivering successful results in the most complex matters. With a powerful combination of scale and agility, we offer clients innovative and effective solutions, while remaining flexible to adapt to their needs and market developments. Known for a collaborative culture, as well as our diversity and pro bono achievements, Hughes Hubbard has a distinguished history dating back more than a century. For more information, visit hugheshubbard.com.